Allakos Inc.

(ALLK) Trade

By |

Profile

Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK002, an antibody that targets Siglec-8, an inhibitory receptor found on eosinophils and mast cells. In preclinical and clinical studies, AK002 has been shown to deplete eosinophils and inhibit mast cells.

Contact Information

Website: www.allakos.com
Email: ir@allakos.com
Main Phone: +1 650 597-5002
Address: 975 Island Drive
Address 2: Suite 201
State: CA
City / Town: Redwood
Country: USA
Postal Code: 94065

Issuer Information

Exchange: NGS
CEO: Robert Alexander
Employees: 77
NAICS: Pharmaceutical Preparation Manufacturing(325412)

Equities News

Profile

Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK002, an antibody that targets Siglec-8, an inhibitory receptor found on eosinophils and mast cells. In preclinical and clinical studies, AK002 has been shown to deplete eosinophils and inhibit mast cells.

Contact Information

Website: www.allakos.com
Email: ir@allakos.com
Main Phone: +1 650 597-5002
Address: 975 Island Drive
Address 2: Suite 201
State: CA
City / Town: Redwood
Country: USA
Postal Code: 94065

Issuer Information

Exchange: NGS
CEO: Robert Alexander
Employees: 77
NAICS: Pharmaceutical Preparation Manufacturing(325412)

Equities News

$ 69.89 $ -5.73 (-7.58%)
Last Price 69.89 Change $ -5.73 Change % -7.58 Tick N/A
Bid N/A Bid Size 0.00 Ask 86.34 Ask Size 100.00
Open 75.69 High 76.34 Low 69.89 Prev Close 75.62
Last Trade Volume 406,823 52 Wk Hi 140.00 52 Wk Low 30.32
Market Cap 3.4 bi Ex-Div Date N/A Div Rate N/A Yield N/A
Shares 48,665,674.00 EPS (TTM) -1.24 PE Ratio N/A Exchange NGS